Bristol-Myers Squibb’s aquisition of Celgene may generate a significant tax burden for Celgene stockholders.
Join our 30 minute webinar on:
- Planning for the conversion of Celgene stock options and restricted stock to Bristol-Myers Squibb awards
- Using unrealized losses to offset taxable gains in Celgene
- Various Charitable Giving Strategies
- Qualified Opportunity Zones
- Defective Grantor Trust
Thursday, January 24
This session is not a substitute for personalized advice from RegentAtlantic. Please be sure to consult with your tax or legal advisors.